Tarsus Pharmaceuticals Book Value 2011-2026 | TARS

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Tarsus Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
343 M	225 M	197 M	193 M	167 M	166 M	-6 M	-1.35 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
343 M	-6 M	160 M

Quarterly Book Value Tarsus Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
335 M	333 M	342 M	225 M	237 M	252 M	275 M	197 M	214 M	148 M	173 M	193 M	203 M	222 M	149 M	167 M	179 M	192 M	183 M	166 M	166 M	166 M	166 M	57.4 M	57.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
342 M	57.4 M	200 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
argenx SE ARGX	5.5 B	$ 834.06	0.94 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	-163 M	$ 234.24	-0.3 %	$ 5 B	Danmark
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Aptorum Group Limited APM	11.8 M	$ 0.81	1.31 %	$ 4.42 M	China
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Atea Pharmaceuticals AVIR	439 M	$ 4.66	1.42 %	$ 393 M	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Axsome Therapeutics AXSM	88.3 M	$ 167.61	-4.09 %	$ 8.34 B	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.33	0.79 %	$ 8.01 B	Australia
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
BioVie BIVI	19 M	$ 1.25	0.4 %	$ 1.85 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
BioMarin Pharmaceutical BMRN	5.66 B	$ 63.02	0.15 %	$ 12 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
CASI Pharmaceuticals CASI	108 M	$ 0.79	4.29 %	$ 108 M	USA
Catalyst Biosciences CBIO	78.5 M	$ 12.71	10.81 %	$ 837 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Capricor Therapeutics CAPR	22.6 M	$ 27.89	0.07 %	$ 747 M	USA
Aptose Biosciences APTO	-4.54 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Aridis Pharmaceuticals ARDS	-24.2 M	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	19.4 B	$ 110.88	0.86 %	$ 27.2 B	Germany
Amneal Pharmaceuticals AMRX	3.5 B	$ 14.72	2.08 %	$ 4.55 B	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Certara CERT	1.06 B	$ 6.67	2.77 %	$ 1.07 B	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA
Burford Capital Limited BUR	1.66 B	$ 9.32	1.25 %	$ 1.5 B	Britain
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
Autolus Therapeutics plc AUTL	427 M	$ 1.85	6.65 %	$ 472 M	Britain